Companies › Otsuka
17 active drug programs in 33 registered trials: 15 Phase 1, 12 Phase 3, 6 Phase 2; Metabolic and endocrine, Psychiatry, Immunology, Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sibeprenlimab Tumor necrosis factor ligand superfamily member 13 inhibitor | TNFSF13 | Phase 3 | Immunoglobulin A Nephropathy; Sjogren Disease; IgA Nephropathy | Jan 2027 |
| Centanafadine (EB-1020) Monoamine transporter inhibitor | SLC6A4, SLC6A3, SLC6A2 | Phase 3 | Attention-Deficit Hyperactivity Disorder(ADHD); Attention Deficit Hyperactivity Disorder (ADHD) | Aug 2027 |
| Brexpiprazole Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist | DRD2, HTR1A, HTR2A | Phase 3 | Acute Schizophrenia | Sep 2027 |
| JNT-517 Phenylalanine ammonia-lyase enzyme replacement | – | Phase 3 | Phenylketonuria (PKU); Phenylketonuria | Nov 2027 |
| Quabodepistat Mycolic acid biosynthesis inhibitor (FABB inhibitor) | FABB | Phase 3 | Rifampicin-Resistant Pulmonary Tuberculosis | Sep 2028 |
| Ulotaront (SEP-363856) Serotonin 1a (5-HT1a) receptor agonist; Trace amine-associated receptor 1 agonist | HTR1A, TAAR1 | Phase 3 | Schizophrenia; Generalized Anxiety Disorder | Oct 2028 |
| Tolvaptan (OPC-41061) Vasopressin V2 receptor antagonist | AVPR2 | Phase 3 | Autosomal Recessive Polycystic Kidney (ARPKD) | Dec 2028 |
| Ponatinib Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 2 | Chronic Myeloid Leukemia | – |
| Repinatrabit (JNT517) | – | Phase 1 | Healthy Volunteers; Phenylketonuria | Nov 2026 |
| VIS171 | – | Phase 1 | Systemic Lupus Erythematosus (SLE) | Feb 2027 |
| ASTX727 Decitabine and cedazuridine combination; decitabine is a DNA methyltransferase inhibitor | DNMT1 | Phase 1 | Myelodysplastic Syndromes | Jun 2027 |
| OPF-310 Encapsulated porcine pancreatic islet cells | – | Phase 1 | Diabetes Mellitus, Type 1 | Jun 2027 |
| NDI-5001 Vasopressin V2 receptor agonist | AVPR2 | Phase 1 | Diabetes Insipidus | Aug 2027 |
| OJP-001 Photodynamic therapy system combining 5-ALA-based PDT with extracorporeal circulation ther | – | Phase 1 | Adult T-Cell Leukemia/Lymphoma (ATLL) | Feb 2028 |
| HBM7020 B-cell targeting therapy | – | Phase 1 | Rheumatoid Arthritis | Nov 2028 |
| ASTX727 Oral decitabine and cedazuridine combination; cedazuridine inhibits cytidine deaminase to | DNMT1 | Phase 1 | Lower-risk Myelodysplastic; Malignant Peripheral Nerve Sheath Tumors (MPNST); Non Small Cell Lung Cancer; Neurological Cancer … | – |
| OPF-110 20% lipid injectable emulsion containing fish oil and medium-chain triglycerides | – | Phase 1 | Healthy Volunteers | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04233346 | Ponatinib | Phase 2 | Chronic Myeloid Leukemia | Oncology | Jul 2022 |
| NCT03906695 | ASTX727 | Phase 1 | Lower-risk Myelodysplastic | Hematology | Jan 2026 |
| NCT02998567 | ASTX727 | Phase 1 | Non Small Cell Lung Cancer | Oncology | Sep 2026 |
| NCT07848334 | OPF-110 | Phase 1 | Healthy Volunteers | Other | Oct 2026 |
| NCT06894212 | Ulotaront (SEP-363856) | Phase 3 | Schizophrenia | Psychiatry | Oct 2026 |
| NCT07446400 | Repinatrabit (JNT517) | Phase 1 | Healthy Volunteers | Metabolic and endocrine | Nov 2026 |
| NCT03922555 | ASTX727 | Phase 1 | Neurological Cancer | Oncology | Jan 2027 |
| NCT05248646 | Sibeprenlimab | Phase 3 | Immunoglobulin A Nephropathy | Genitourinary | Jan 2027 |
| NCT07713758 | Repinatrabit (JNT517) | Phase 1 | Phenylketonuria | Metabolic and endocrine | Feb 2027 |
| NCT06799520 | VIS171 | Phase 1 | Systemic Lupus Erythematosus (SLE) | Immunology | Feb 2027 |
| NCT06928142 | Sibeprenlimab | Phase 2 | Sjogren Disease | Immunology | Mar 2027 |
| NCT04872543 | ASTX727 | Phase 2 | Malignant Peripheral Nerve Sheath Tumors (MPNST) | Oncology | Apr 2027 |
| NCT06575426 | OPF-310 | Phase 1 | Diabetes Mellitus, Type 1 | Metabolic and endocrine | Jun 2027 |
| NCT06091267 | ASTX727 | Phase 1 | Myelodysplastic Syndromes | Hematology | Jun 2027 |
| NCT07087327 | Centanafadine (EB-1020) | Phase 3 | Attention-Deficit Hyperactivity Disorder(ADHD) | Psychiatry | Aug 2027 |
| NCT07086313 | Centanafadine (EB-1020) | Phase 2 | Attention-Deficit Hyperactivity Disorder(ADHD) | Psychiatry | Aug 2027 |
| NCT04061421 | ASTX727 | Phase 1 | MDS/MPN | Oncology | Aug 2027 |
| NCT07525960 | NDI-5001 | Phase 1 | Diabetes Insipidus | Metabolic and endocrine | Aug 2027 |
| NCT05325645 | Brexpiprazole | Phase 3 | Acute Schizophrenia | Psychiatry | Sep 2027 |
| NCT06628128 | JNT-517 | Phase 3 | Phenylketonuria (PKU) | Metabolic and endocrine | Nov 2027 |
| NCT06926829 | Centanafadine (EB-1020) | Phase 3 | Attention Deficit Hyperactivity Disorder (ADHD) | Psychiatry | Dec 2027 |
| NCT06931080 | Centanafadine (EB-1020) | Phase 2 | Attention Deficit Hyperactivity Disorder (ADHD) | Psychiatry | Dec 2027 |
| NCT06177171 | ASTX727 | Phase 1 | BRCA1 Mutation | Other | Jan 2028 |
| NCT07075328 | OJP-001 | Phase 1 | Adult T-Cell Leukemia/Lymphoma (ATLL) | Oncology | Feb 2028 |
| NCT06971731 | JNT-517 | Phase 3 | Phenylketonuria | Metabolic and endocrine | Mar 2028 |
| NCT07209761 | Quabodepistat | Phase 3 | Rifampicin-Resistant Pulmonary Tuberculosis | Infectious disease | Sep 2028 |
| NCT07767903 | Ulotaront (SEP-363856) | Phase 3 | Generalized Anxiety Disorder | Psychiatry | Oct 2028 |
| NCT07649265 | HBM7020 | Phase 1 | Rheumatoid Arthritis | Immunology | Nov 2028 |
| NCT07759128 | Ulotaront (SEP-363856) | Phase 3 | Generalized Anxiety Disorder | Psychiatry | Dec 2028 |
| NCT06740526 | Sibeprenlimab | Phase 2 | IgA Nephropathy | Genitourinary | Dec 2028 |
| NCT04782258 | Tolvaptan (OPC-41061) | Phase 3 | Autosomal Recessive Polycystic Kidney (ARPKD) | Genitourinary | Dec 2028 |
| NCT05178693 | ASTX727 | Phase 1 | Neuroendocrine Tumors | Oncology | Feb 2029 |
| NCT07786454 | Ulotaront (SEP-363856) | Phase 3 | Generalized Anxiety Disorder | Psychiatry | May 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.